Price T Rowe Associates Inc. MD Boosts Position in Accolade, Inc. (NASDAQ:ACCD)

Price T Rowe Associates Inc. MD raised its stake in shares of Accolade, Inc. (NASDAQ:ACCD) by 16.8% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 27,673 shares of the company’s stock after purchasing an additional 3,982 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Accolade were worth $95,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Fairman Group LLC boosted its stake in Accolade by 58.5% during the fourth quarter. Fairman Group LLC now owns 1,802,399 shares of the company’s stock valued at $6,164,000 after buying an additional 665,112 shares during the last quarter. Whetstone Capital Advisors LLC increased its holdings in Accolade by 58.9% during the 4th quarter. Whetstone Capital Advisors LLC now owns 1,585,643 shares of the company’s stock worth $5,423,000 after purchasing an additional 587,754 shares during the period. Dimensional Fund Advisors LP boosted its position in Accolade by 0.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,513,275 shares of the company’s stock valued at $5,175,000 after acquiring an additional 3,885 shares in the last quarter. Kennedy Capital Management LLC boosted its position in Accolade by 40.9% during the 4th quarter. Kennedy Capital Management LLC now owns 1,065,757 shares of the company’s stock valued at $3,645,000 after acquiring an additional 309,201 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Accolade by 84.1% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 634,470 shares of the company’s stock worth $2,170,000 after purchasing an additional 289,747 shares in the last quarter. Institutional investors own 84.99% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Piper Sandler cut Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Stephens restated an “equal weight” rating and issued a $7.03 price target on shares of Accolade in a research note on Wednesday, February 12th. Thirteen investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $6.51.

Accolade Stock Performance

Shares of Accolade stock opened at $7.02 on Monday. The firm has a market capitalization of $575.59 million, a price-to-earnings ratio of -3.12 and a beta of 2.10. Accolade, Inc. has a fifty-two week low of $3.08 and a fifty-two week high of $7.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.63. The stock has a 50 day moving average of $7.01 and a 200 day moving average of $5.81.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.